Literature DB >> 17451792

Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation.

ShiJun Li1, XiaoYing Li, Jian Li, XinLi Deng, Yan Li, Yulong Cong.   

Abstract

OBJECTIVES: The aim of our study is to elucidate whether experimental arterial thrombosis is regulated by physiological doses of androgen and its receptor via modulation of platelet activation.
METHODS: Surgical castration was performed in male rats and ferric chloride (FeCl(3)), as a stimulator, induced the experimental arterial thrombosis. Testosterone was measured directly by chemiluminescent immunoassay on the Bayer ADVIA Centaur analyzer. Dihydrotestosterone (DHT) was determined by ELISA using a commercially available kit. A platelet aggregometer was used to assess aggregation, and a platelet adherometer was used to measure adhesion. The contents of TXB(2) and 6-Keto-PGF(1alpha) were assayed by radio-immunoassay using commercially available kits.
RESULTS: Our data showed that DHT replaced restored circulating DHT of castrated rats to physiological levels, without being altered by treatment with flutamide. Castration caused significant increases in the thrombus area and weight in castrated rats as compared with control group. In PRP diluted with autologous PPP, ADP-induced platelet aggregation rate was only 9.10%. However, in PRP diluted with Tyrode's buffer, 1 microM ADP-induced platelet aggregation rate rose to 63.65%. In PRP diluted with Tyrode's buffer, and pretreated with DHT (1 nM, 2 nM), ADP-induced platelet aggregation was significantly lowered again. Platelet aggregation in PRP diluted with autologous PPP was enhanced in castrated rats as compared with sham-operated rats, and DHT (2 nM) replacement suppressed platelet aggregation in castrated PRP to the level similar to that of sham-operated rats. However, presence of flutamide (3 microM) significantly increased platelet aggregation in PRP diluted with autologous PPP or Tyrode's buffer. DHT (2 nM) replacement significantly inhibited the ADP-induced platelet adhesion. However, presence of flutamide (3 microM) increased ADP-induced platelet adhesion again. DHT replacement obviously reduced the ratio of TXB(2) to 6-keto-PGF(1alpha) in castrated rats. However, administration of flutamide and DHT to castrated rats caused an increase in the ratio of TxB(2) to 6-keto-PGF1alpha.
CONCLUSION: Inhibition of experimental arterial thrombosis by androgen at physiological doses and its receptor is mediated via modulation of platelet activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451792     DOI: 10.1016/j.thromres.2007.03.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  18 in total

1.  Androgen deprivation and thromboembolic events in men with prostate cancer.

Authors:  Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

Review 2.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

3.  Antiplatelet activity of 3-butyl-6-bromo-1(3H)-isobenzofuranone on rat platelet aggregation.

Authors:  Feifei Ma; Yuan Gao; Hailing Qiao; Xiangjie Hu; Junbiao Chang
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

4.  Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

Authors:  Dawn L Hershman; Joseph M Unger; Jason D Wright; Scott Ramsey; Cathee Till; Catherine M Tangen; William E Barlow; Charles Blanke; Ian M Thompson; Maha Hussain
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

Review 5.  Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Dipti Gupta; Chadi Salmane; Susan Slovin; Richard M Steingart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

6.  Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Authors:  Jim C Hu; Stephen B Williams; A James O'Malley; Matthew R Smith; Paul L Nguyen; Nancy L Keating
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

7.  Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.

Authors:  Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg
Journal:  Lancet Oncol       Date:  2010-04-13       Impact factor: 41.316

Review 8.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30

Review 9.  Gender and the injured brain.

Authors:  Kamila Vagnerova; Ines P Koerner; Patricia D Hurn
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

Review 10.  Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.

Authors:  Marlon Perera; Matthew J Roberts; Laurence Klotz; Celestia S Higano; Nathan Papa; Shomik Sengupta; Damien Bolton; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2020-06-30       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.